- Guide to PHARMACOLOGY
Synonyms: Arcoxia® | MK 0663 | MK-0663 | MK0663
etoricoxib is an approved drug
Compound class: Synthetic organic
Comment: Etoricoxib is a selective COX-2 inhibitor, non-steroidal anti-inflammatory (NSAID) drug.
COVID-19: Etoricoxib offers potential to be repositioned to inhibit cytokine storm in COVID-19 patients .
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
View more information in the IUPHAR Pharmacology Education Project: etoricoxib
1. Riendeau D, Percival MD, Brideau C, Charleson S, Dubé D, Ethier D, Falgueyret JP, Friesen RW, Gordon R, Greig G et al.. (2001)
Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2.
J Pharmacol Exp Ther, 296 (2): 558-66. [PMID:11160644]
2. Wang R. (2021)
Etoricoxib may inhibit cytokine storm to treat COVID-19.
Med Hypotheses, 150: 110557. [PMID:33730601]